[go: up one dir, main page]

WO2016115250A1 - Cigarette électronique ou fluide de vapotage amélioré - Google Patents

Cigarette électronique ou fluide de vapotage amélioré Download PDF

Info

Publication number
WO2016115250A1
WO2016115250A1 PCT/US2016/013248 US2016013248W WO2016115250A1 WO 2016115250 A1 WO2016115250 A1 WO 2016115250A1 US 2016013248 W US2016013248 W US 2016013248W WO 2016115250 A1 WO2016115250 A1 WO 2016115250A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
concentration
volume
cyclodextrin
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/013248
Other languages
English (en)
Inventor
Shyam KUNTAWALA
Lawrence Moy
Ashish Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016115250A1 publication Critical patent/WO2016115250A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
    • A24B15/284—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances the additive being bound to a host by chemical, electrical or like forces, e.g. use of precursors, inclusion complexes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/308—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Definitions

  • the current invention is in the area of e-cigarettes and "vaping" and concerns an improved non-nicotine fluid for e-cigarette devices.
  • Smoking has a long history in human cultures. When plant materials are burned various organic chemicals that are constituents of the plant vaporize and attach themselves to the smoke particles. At the same time heat and combustion break down constituent organic chemicals and produce new chemicals all of which are present in the vapor state and/or attach themselves to the smoke particles. When the smoke is inhaled, the particles come into contact with the surface of lung cells and the chemicals absorbed to the particles transfer to the lung cells and eventually are transferred into the circulatory system. Because of the extremely large surface area of the lung, smoking is an extremely effective route for administering active compounds. Because plants contain a wide variety of secondary products inhaling the smoke delivers these products to the human body. The physiological results can be stimulation, depression or even hallucination depending on what type of plant is burned to produce the smoke.
  • tobacco smoking is highly addictive as in the case of nicotine in tobacco smoke.
  • tobacco has become the primary plant material that is smoke worldwide— to the point that "smoking" has become essentially synonymous with "tobacco smoking.”
  • tobacco smoking was once considered to be a benign or even healthful pastime, it is now considered to be a health hazard.
  • tobacco smoking is major cause of lung as well as other cancers in smokers as well as those exposed to "second hand” smoke.
  • smoking tobacco and heart is well as vascular disease.
  • e-cigarettes have been developed as a safer alternative to smoking tobacco.
  • a mechanism reduces a liquid ("e-cigarette fluid,” “e- fluid” or “vaping fluid”) into a smoke-like mixture of air and tiny droplets (an aerosol) which material is then inhaled. Any active constituents in the vaping fluid are then absorbed by the lungs like real smoke.
  • e-cigarettes do not produce smoke, other terms have been developed to describe using the devices.
  • vaping One such term that is gaining popularity is "vaping.”
  • E-cigarettes are thought to be safer than smoking tobacco because nothing is actually burned in an e- cigarette.
  • the most common type of e-cigarette has a heating element which vaporizes the e-fluid to create an aerosol. Less commonly there is mechanical production of the aerosol. For example, some devices use a piezoelectric diaphragm which vibrates at ultrasonic speeds to directly form an aerosol from the e-fluid rather like a cool-mist humidifier.
  • e-fluids contain nicotine (approximately 0.04M-0.12M) so that vaping an e- cigarette can act as a substitute for smoking tobacco by delivering nicotine to the user.
  • nicotine e-cigarettes As smoking cessation devices. The idea is that the users transition to the e-cigarettes and then use e-fluids with diminishing levels of nicotine until the user's nicotine addiction is overcome.
  • many users alternate between "real" cigarettes and e-cigarettes so the usefulness of vaping e- cigarettes as an aid to smoking cessation is somewhat questionable.
  • the e- cigarette avoids the dangers of secondhand tobacco smoke.
  • vaping fluids can be obtained by combining a variety of active ingredients with the hydrophilic solvents typical of such fluids.
  • the active ingredients are chosen depending on the desired effects of using the fluid.
  • methylzanthines such as caffeine can be used to provide an energy boost product.
  • Energy boost formulae can also contain taurine, cyanocobalamin, carnitine, guarana, and ginseng.
  • Relaxation/sleep formulae can include chamomile, valerian, kava and other active ingredients.
  • Appetite suppressant formulae can contain hoodia, yerba mate, caralluma and lecithin.
  • scents/flavors and colors can also be included. It is preferred to used natural plant extracts to impart colors.
  • Cyclodextrin is included to enhance absorption of the active ingredients as well as to limit any tendency of the inhaled aerosol to cause irritation.
  • e-fluids contain water and one or more hydrophilic solvent such as glycerol, propylene glycol and/or polyethylene glycol.
  • the hydrophilic solvent is important for the production of aerosols by a heat source. When a water solution of these solvents contacts a heat source, the water rapidly vaporizes leaving behind an aerosol of hydrophilic solvent particles which contain the other ingredients that were dissolved in the original e-fluid and/or the other ingredients are present as tiny particles.
  • the "other ingredients” include flavors, scents and additives intended to enhance the efficacy of the other ingredients.
  • the ingredients must be carried into the user's lungs. This generally occurs because the ingredients are bound to or dissolved in the aerosol particles.
  • the aerosol particles may not always be of optimum size so that they are filtered out by lung structures before there is a chance for the active ingredients to be properly absorbed. In other cases the aerosol particles are somewhat irritating to the user's throat and other tissues.
  • cyclodextrins are useful for sequestering hydrophobic molecules and for forming droplets in a nebulizer.
  • cyclodextrins also promote aerosol formation with the heating elements of common e-cigarettes (as well as with the spray jets of nebulizers). More importantly, the addition of sufficient cyclodextrin to e-fluid enhances the absorption and bioavailability of any active ingredients while at the same time reducing any tendency towards irritation caused by the aerosol.
  • the cyclodextrin molecules form a somewhat conical structure—that is, a hollow cylinder having a smaller opening at one end than the other.
  • the cyclodextrin molecule in solution has an interior that is more hydrophobic than its exterior (i.e., the exterior is relatively hydrophilic).
  • the molecule to be sequestered must be at least partially hydrophobic and of dimensions to fit within the cyclodextrin ring.
  • Active ingredients such as methylxanthines and nicotine are of the right size for sequestration and are essentially hydrophobic at physiological and acid pHs.
  • cyclodextrin is affected by the active ingredient as well as the other ingredients in the e-fluid formula. Both a and ⁇ cyclodextrin have a water solubility that is approximately an order of magnitude higher than that of ⁇ cyclodextrin. Therefore, if it is desired to use a relatively high level of active ingredient, a and ⁇ cyclodextrin are preferred. Otherwise, ⁇ cyclodextrin operates adequately.
  • a methylxanthine alkaloid such as caffeine is combined with taurine which has beneficial biological as well as surfactant properties.
  • methylxanthine alkaloids improve energy and provide a feeling of well- being.
  • Taurine is a natural amino acid derivative that has an anti-anxiety effect as well as many health benefits.
  • taurine has surfactant properties and aids in the dispersion of insoluble ingredients.
  • Caffeine is effective in e-fluids of 0.01 M to 0.15M. Much below this concentration range, there is little discernible effect whereas at much higher concentrations, the caffeine effect can be excessive. Currently, a concentration of 0.05M is preferred.
  • Taurine has a wide effective range of at least 0.01 M to 0.1 M; currently 0.015M is preferred.
  • cyanocobalamin vitamin B12
  • This water soluble vitamin is important for many cellular functions and seems to potentiate the effects of caffeine and taurine.
  • the cyanocobalamin has a red-magenta color and can be used as the sole coloring agent or other colors may be added as desired. This has been tested at concentrations between 0.01 % and 0.1%; currently 0.083% (weight by volume) is preferred.
  • Other common methylxanthines such as theophylline or theobromine can be substituted or used in conjunction with caffeine.
  • Extracts of guarana can be used to supply caffeine as well as other beneficial natural ingredients. Extracts of Ginkgo biloba can be used to supply antioxidants Extracts of ginseng (Panax species) are also effective when combined with cyclodextrins. Finally, carnitine is effective in energy formulae. These ingredients are generally used at concentration of about 0.5% by weight or less.
  • Caffeine, other methylxanthines and taurine can be stabilized as metal complexes (zinc, magnesium and/or sodium) and/or cyclodextrin complexes.
  • Metal complexes are formed by adding a molar excess of a water soluble salt of the desired metal. Cyclodextrin complexes form best with a molar excess of cyclodextrin. It has been found that a 2-3 fold molar excess works well although cyclodextrin is effective in the range of 0.5 to 5.0 molar ratio of cyclodextrin to active ingredient. Cyclodextrin is used preferable but can be used with the metal complex as well. That is, the required concentration of both metal and cyclodextrin can be used.
  • the main vehicle is an approximately 50% aqueous solution of high boiling point hydrophilic solvent. It is not essential that the fluid be precisely 50% water. Typically either glycerol and/or propylene glycol are used as hydrophilic solvents. This translates to a 5.4M glycerol or a 6.6M propylene glycol solution. Tests suggest that a solution being at least about 2M of either of these solvents (or a combination thereof) is adequate. Using excess hydrophilic solvent increases both the cost and viscosity of the product. The hydrophilic solvents increase the solubility of the active ingredients and act as particle formers when the e-cigarette mechanism boils away much of the water. Without these solvents aerosol formation would be much less efficient.
  • the inactive ingredients include a variety of flavors and/or scents. Actually, these additives are primarily scents because the human sense of taste is primarily limited to sweet, salty, sour, bitter and umami. What we perceive of as "orange" flavor or taste is actually orange scent combined with a taste of sweet and sour.
  • the glycerol and propylene glycol components of the vehicle have an actual sweet taste that can be detected by most users. Depending on the pH of the vehicle there may also be a slight sour (low pH) taste. If active ingredients such as caffeine or nicotine are present at sufficiently high concentrations, there may also be an actual discernible bitter taste. Useful scents are practically unlimited.
  • mint-related scents are useful in e-fluid.
  • fruit flavors i.e., orange and banana
  • scents such as vanilla.
  • the preferred "flavors” are green apple, vanilla cupcake, blueberry, and mango.
  • various herbal, musky and other scents may also be appropriate. Generally, these are used at very low concentrations. Generally, under 0.1 % by volume. Many of the plant extracts mentioned above also provide a unique flavor/scent.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • Ginkgo biloba extract 0.25% (volume by volume)
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60 °C to ensure that the scent/flavor is properly dispersed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des fluides de vapotage pour la stimulation de l'énergie, la relaxation l'appétit et d'autres fonctions, qui contiennent des ingrédients actifs combinés à de la cyclodextrine pour améliorer l'absorption et éviter l'irritation. Les ingrédients actifs comprennent la caféine, la théophylline, le maté et la valériane ainsi que la taurine, la carnitine et le L-tryptophane. Les ingrédients actifs sont combinés à une solution aqueuse de solvants hydrophiles (tels que la glycérine ou le propylène glycol) ainsi qu'à des traces de parfums ou d'arômes.
PCT/US2016/013248 2015-01-13 2016-01-13 Cigarette électronique ou fluide de vapotage amélioré Ceased WO2016115250A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562102894P 2015-01-13 2015-01-13
US62/102,894 2015-01-13
US14/984,774 2015-12-30
US14/984,774 US20160198759A1 (en) 2015-01-13 2015-12-30 E-cigarette or vaping fluid

Publications (1)

Publication Number Publication Date
WO2016115250A1 true WO2016115250A1 (fr) 2016-07-21

Family

ID=56366526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/013248 Ceased WO2016115250A1 (fr) 2015-01-13 2016-01-13 Cigarette électronique ou fluide de vapotage amélioré

Country Status (2)

Country Link
US (1) US20160198759A1 (fr)
WO (1) WO2016115250A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021056526A1 (fr) * 2019-09-27 2021-04-01 深圳雾芯科技有限公司 Liquide de cigarette électronique
US11206872B2 (en) 2020-04-07 2021-12-28 Consumernext Labs Gmbh Stable-foam dispensing device and cartridge
RU2770248C1 (ru) * 2018-11-01 2022-04-14 Никовенчерс Трейдинг Лимитед Способная образовывать аэрозоль композиция
US12193471B2 (en) 2018-11-01 2025-01-14 Nicoventures Trading Limited Aerosolizable formulation
US12419339B2 (en) 2018-11-01 2025-09-23 Nicoventures Trading Limited Aerosolized formulation

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160345631A1 (en) 2005-07-19 2016-12-01 James Monsees Portable devices for generating an inhalable vapor
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
KR102256888B1 (ko) 2013-12-23 2021-05-31 쥴 랩스, 인크. 기화 디바이스 시스템 및 방법
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
EP3821735B1 (fr) 2014-12-05 2024-11-20 Juul Labs, Inc. Commande de dose graduée
US10039320B2 (en) 2015-05-14 2018-08-07 Lunatech, Llc Multi-chambered vaporizer and blend control
WO2016187115A1 (fr) 2015-05-15 2016-11-24 John Cameron Système de distribution de vapeur hybride utilisant des éléments nébulisés et non nébulisés
US9770055B2 (en) 2015-05-15 2017-09-26 Lunatech, Llc Vaporizable material handling for electronic vapor device
US10088463B2 (en) 2015-06-11 2018-10-02 Lunatech, Llc Calibrating electronic vapor device
US10060639B2 (en) 2015-06-11 2018-08-28 Lunatech, Llc Air analyzer and treatment apparatus
US9933790B2 (en) 2015-06-15 2018-04-03 Lunatech, Llc Peer-to-peer air analysis and treatment
US10215430B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Electronic vapor and analysis with HVAC integration
US10215429B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Localized air sensing and treatment
US10042369B2 (en) 2015-06-16 2018-08-07 Lunatech, Llc Vapor device for filtering and testing material
US10065138B2 (en) 2015-06-17 2018-09-04 Lunatech, Llc Remote controllable air treatment apparatus
US9888725B2 (en) 2015-07-28 2018-02-13 Lunatech, Llc Inhalation puff counter gauge and display system
US9936737B2 (en) 2015-10-28 2018-04-10 Lunatech, Llc Methods and systems for a dual function vapor device
MX377347B (es) 2016-02-11 2025-03-07 Juul Labs Inc Cartucho rellenable de vaporizador y metodo de relleno
EP3419443A4 (fr) 2016-02-11 2019-11-20 Juul Labs, Inc. Cartouches fixées de manière sure pour des dispositifs de vaporisation
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
US20180338905A1 (en) * 2017-05-26 2018-11-29 Inhale Health, LLC Bioavailable aerosolized supplement formulations
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
GB201718033D0 (en) * 2017-11-01 2017-12-13 Nicoventures Holdings Ltd Flavoured vaporisable formulation
GB2569940B (en) 2017-11-01 2022-10-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817867D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
EP3873249B1 (fr) * 2018-11-01 2024-02-14 Nicoventures Trading Limited Formulation aérosolisable
GB201817861D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
GB201817859D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
WO2020097341A1 (fr) 2018-11-08 2020-05-14 Juul Labs, Inc. Cartouches pour dispositifs de vaporisateur
WO2020205676A1 (fr) * 2019-03-29 2020-10-08 V Rush Vapes LLC Composition de suppléments pour athlétisme et entraînement physique, procédé de production et procédé d'administration pulmonaire de celle-ci
WO2021042269A1 (fr) * 2019-09-03 2021-03-11 深圳雾芯科技有限公司 Liquide pour cigarette électronique
GB202011092D0 (en) * 2020-07-17 2020-09-02 Nicoventures Trading Ltd Consumable
WO2022049512A1 (fr) * 2020-09-03 2022-03-10 Rai Strategic Holdings, Inc. Formulation aérosolisable
CN114299688B (zh) * 2021-12-29 2023-08-08 深圳市希格莱特科技有限公司 一种基于电子烟雾检测的烟油成分识别方法及系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
WO2003077846A2 (fr) * 2002-03-11 2003-09-25 Caplan Jay L Nouvelle methode therapeutique d'administration de medicament permettant d'eviter les effets d'irritation sur les membranes d'un utilisateur
WO2010044736A1 (fr) * 2008-10-14 2010-04-22 Mcneil Ab Forme posologique intra-orale à parties multiples et son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
WO2003077846A2 (fr) * 2002-03-11 2003-09-25 Caplan Jay L Nouvelle methode therapeutique d'administration de medicament permettant d'eviter les effets d'irritation sur les membranes d'un utilisateur
WO2010044736A1 (fr) * 2008-10-14 2010-04-22 Mcneil Ab Forme posologique intra-orale à parties multiples et son utilisation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770248C1 (ru) * 2018-11-01 2022-04-14 Никовенчерс Трейдинг Лимитед Способная образовывать аэрозоль композиция
US12193471B2 (en) 2018-11-01 2025-01-14 Nicoventures Trading Limited Aerosolizable formulation
US12419339B2 (en) 2018-11-01 2025-09-23 Nicoventures Trading Limited Aerosolized formulation
WO2021056526A1 (fr) * 2019-09-27 2021-04-01 深圳雾芯科技有限公司 Liquide de cigarette électronique
US11206872B2 (en) 2020-04-07 2021-12-28 Consumernext Labs Gmbh Stable-foam dispensing device and cartridge

Also Published As

Publication number Publication date
US20160198759A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
WO2016115250A1 (fr) Cigarette électronique ou fluide de vapotage amélioré
KR101956318B1 (ko) 흡연의 화학적 감각을 모사하기 위한 장치 및 방법
JP5524832B2 (ja) 吸入可能な組成物を放出するための加圧容器及び当該加圧容器を含む装置
WO2014201735A1 (fr) Liquide atomisé oral avec substitut de nicotine cytisine et son procédé de préparation
WO2016133890A1 (fr) Compositions pour cigarettes électroniques
EP2941135B1 (fr) Substitut de tabac
KR20100028182A (ko) 전자 담배용 니코틴 수용액
CN104585862B (zh) 一种无甜腻感电子烟烟液
RS64142B1 (sr) Kompozicija
WO2021035103A1 (fr) Formulation de nicotine pour nébuliseur à mailles actives
CN104970445B (zh) 一种缓释型气雾口香烟
CN105054281B (zh) 一种气雾型口香烟
ES3036472T3 (en) Agents for modulating the sensory impact of tobacco or herbal smoke
KR20110023949A (ko) 금연보조담배용 가연성 무화용액
CN105361237A (zh) 一种具有降低胆固醇功效的电子烟烟液及其制备方法
EP2888951A1 (fr) Produit comprenant du kratom
JP2024531502A (ja) 噴霧投与用の医用液体組成物
LU100976B1 (en) New tobacco substitutes
JP2002281939A (ja) 生薬食料製品
JP2025537767A (ja) エアロゾル化可能な配合物のための消耗品
Novikova et al. Are E-Cigarettes Safer than Cigarette Smoking?
CN101356994A (zh) 健康香烟
KR20190018846A (ko) 금연초용 조성물 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16702620

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16702620

Country of ref document: EP

Kind code of ref document: A1